Amygdala Neurosciences

10:45 AM - 11:00 AM, Tuesday, October 22, 2019 ・ 2nd Floor
Amygdala is developing ANS-6637, a selective ALDH2 enzyme inhibitor, as a treatment for opioid, alcohol and nicotine addiction. With a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 intervenes in the reward circuit to prevent cue-based craving and drug seeking behavior. ANS-6637 is different than any other approved or development treatment in for addiction: it does not have abuse liability, is not a agonist (like buprenorphine), is not an antagonist (like naltrexone), is not a scheduled compound, and ANS-6637 can be used alone or in combination with current pharmacotherapy and behavior-based addiction treatments.

ANS-6637 safety and efficacy is being evaluated in Phase 2 POC studies for Opioid Use Disorder and Alcohol Use Disorder and plans are being finalized for for additional Phase-2 POC studies for Smoking Cessation and PTSD.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
ANS-6637
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided